Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 224

Similar articles for PubMed (Select 17622601)

1.

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

Amori RE, Lau J, Pittas AG.

JAMA. 2007 Jul 11;298(2):194-206. Review.

PMID:
17622601
2.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

3.

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

Mikhail N.

Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845 . Review.

PMID:
18491986
4.
5.
6.

A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.

Fakhoury WK, Lereun C, Wright D.

Pharmacology. 2010;86(1):44-57. doi: 10.1159/000314690. Epub 2010 Jul 12. Review.

7.

[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].

Kleefstra N, van Hateren KJ, Houweling ST, Verhoeven S, Kooy A, Goudswaard AN, Bilo HJ.

Ned Tijdschr Geneeskd. 2010;154:A886. Review. Dutch.

PMID:
20298625
8.

GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.

Ahrén B.

Curr Diab Rep. 2007 Oct;7(5):340-7. Review.

PMID:
18173966
9.

Incretin-based therapies in type 2 diabetes: a review of clinical results.

Bosi E, Lucotti P, Setola E, Monti L, Piatti PM.

Diabetes Res Clin Pract. 2008 Dec 15;82 Suppl 2:S102-7. doi: 10.1016/j.diabres.2008.10.003. Epub 2008 Nov 20. Review.

PMID:
19022515
10.

Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.

Siddiqui NI.

Mymensingh Med J. 2009 Jan;18(1):113-24. Review.

PMID:
19182763
11.

Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.

Bourdel-Marchasson I, Schweizer A, Dejager S.

Hosp Pract (1995). 2011 Feb;39(1):7-21. doi: 10.3810/hp.2011.02.369. Review.

PMID:
21441754
12.

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A.

BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369.

13.

[Incretin related agents for treatment of diabetes mellitus].

Miyagawa J, Miuchi M, Nanba M.

Nihon Naika Gakkai Zasshi. 2009 Apr 10;98(4):809-16. Review. Japanese. No abstract available.

PMID:
19472544
14.

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006739. doi: 10.1002/14651858.CD006739.pub2. Review.

PMID:
18425967
15.

Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.

Davidson JA, Parente EB, Gross JL.

Arq Bras Endocrinol Metabol. 2008 Aug;52(6):1039-49. Review.

16.

[Therapeutic use and adverse events of incretin-related drugs].

Ishikawa M, Yamada Y.

Nihon Rinsho. 2012 May;70 Suppl 3:699-702. Japanese. No abstract available.

PMID:
22768601
17.
18.

[New concepts in the treatment of type 2 diabetes].

Meier JJ, Schmidt WE, Klein HH.

Internist (Berl). 2007 Jul;48(7):698, 700-7. Review. German.

PMID:
17541529
19.

[The value of incretin based therapies].

Gallwitz B.

Dtsch Med Wochenschr. 2009 May;134(20):1062-6. doi: 10.1055/s-0029-1222570. Epub 2009 May 6. Review. German. No abstract available.

PMID:
19421931
20.

The role of vildagliptin in the management of type 2 diabetes mellitus.

Kleppinger EL, Helms K.

Ann Pharmacother. 2007 May;41(5):824-32. Epub 2007 Apr 24. Review.

PMID:
17456545
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk